Anbio Biotechnology
NNNN32.350USD
+2.100+6.94%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
4.65BMarket Cap
1939.45P/E TTM
More Details of Anbio Biotechnology Company
Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
Anbio Biotechnology Info
Ticker SymbolNNNN
Company nameAnbio Biotechnology
IPO dateFeb 19, 2025
CEOLau (Michael)
Number of employees27
Security typeOrdinary Share
Fiscal year-endFeb 19
AddressFriedrich-Ebert-Anlage 49
CityFRANKFURT AM MAIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryGermany
Postal code60308
Phone4916096247281
Websitehttps://anbiobiotechnology.com/
Ticker SymbolNNNN
IPO dateFeb 19, 2025
CEOLau (Michael)
Company Executives of Anbio Biotechnology
Name
Name/Position
Position
Shareholding
Change
Ms. Nancy Hartzler
Ms. Nancy Hartzler
Independent Director
Independent Director
--
--
Mr. David Hsu
Mr. David Hsu
Independent Director
Independent Director
--
--
Mr. Kenneth Li
Mr. Kenneth Li
Independent Director
Independent Director
--
--
Mr. Michael Lau
Mr. Michael Lau
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Suki Song
Ms. Suki Song
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Cany Xu
Mr. Cany Xu
Executive Director
Executive Director
--
--
Mr. Chris Tiantian
Mr. Chris Tiantian
Chief Business Officer
Chief Business Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Nancy Hartzler
Ms. Nancy Hartzler
Independent Director
Independent Director
--
--
Mr. David Hsu
Mr. David Hsu
Independent Director
Independent Director
--
--
Mr. Kenneth Li
Mr. Kenneth Li
Independent Director
Independent Director
--
--
Mr. Michael Lau
Mr. Michael Lau
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Suki Song
Ms. Suki Song
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Cany Xu
Mr. Cany Xu
Executive Director
Executive Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
European Union
5.62M
68.64%
South America
1.48M
18.02%
Asia Pacific
509.17K
6.22%
Other Regions
472.38K
5.77%
North America
110.51K
1.35%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Northwestern Mutual Capital, LLC
4.78%
CVC Investment
4.78%
Geode Capital Management, L.L.C.
0.06%
Marshall Wace LLP
0.02%
Morgan Stanley & Co. LLC
0.02%
Other
90.33%
Shareholders
Shareholders
Proportion
Northwestern Mutual Capital, LLC
4.78%
CVC Investment
4.78%
Geode Capital Management, L.L.C.
0.06%
Marshall Wace LLP
0.02%
Morgan Stanley & Co. LLC
0.02%
Other
90.33%
Shareholder Types
Shareholders
Proportion
Investment Advisor
4.80%
Corporation
4.78%
Investment Advisor/Hedge Fund
0.08%
Research Firm
0.03%
Hedge Fund
0.02%
Venture Capital
0.02%
Other
90.28%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
8
2.13M
4.85%
+2.06M
2025Q2
5
4.27M
9.72%
+4.25M
2025Q1
5
4.27M
9.72%
+4.27M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Northwestern Mutual Capital, LLC
2.10M
4.78%
+2.10M
--
Feb 19, 2025
CVC Investment
2.10M
4.78%
+2.10M
--
Feb 19, 2025
Geode Capital Management, L.L.C.
17.13K
0.04%
+70.00
+0.41%
Jun 30, 2025
Marshall Wace LLP
--
0%
-43.63K
-100.00%
Jun 30, 2025
Morgan Stanley & Co. LLC
400.00
0%
+400.00
--
Jun 30, 2025
BNP Paribas Securities Corp. North America
1.26K
0%
+1.26K
--
Jun 30, 2025
UBS Financial Services, Inc.
10.70K
0.02%
+4.96K
+86.39%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Anbio Biotechnology?
The top five shareholders of Anbio Biotechnology are:
Northwestern Mutual Capital, LLC holds 2.10M shares, accounting for 4.78% of the total shares.
CVC Investment holds 2.10M shares, accounting for 4.78% of the total shares.
Geode Capital Management, L.L.C. holds 17.13K shares, accounting for 0.04% of the total shares.
Marshall Wace LLP holds 0.00 shares, accounting for 0.00% of the total shares.
Morgan Stanley & Co. LLC holds 400.00 shares, accounting for 0.00% of the total shares.
Northwestern Mutual Capital, LLC holds 2.10M shares, accounting for 4.78% of the total shares.
CVC Investment holds 2.10M shares, accounting for 4.78% of the total shares.
Geode Capital Management, L.L.C. holds 17.13K shares, accounting for 0.04% of the total shares.
Marshall Wace LLP holds 0.00 shares, accounting for 0.00% of the total shares.
Morgan Stanley & Co. LLC holds 400.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Anbio Biotechnology?
The top three shareholder types of Anbio Biotechnology are:
Northwestern Mutual Capital, LLC
CVC Investment
Geode Capital Management, L.L.C.
Northwestern Mutual Capital, LLC
CVC Investment
Geode Capital Management, L.L.C.
How many institutions hold shares of Anbio Biotechnology (NNNN)?
As of 2025Q3, 8 institutions hold shares of Anbio Biotechnology, with a combined market value of approximately 2.13M, accounting for 4.85% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -4.87%.
What is the biggest source of revenue for Anbio Biotechnology?
In FY2024, the -- business generated the highest revenue for Anbio Biotechnology, amounting to -- and accounting for --% of total revenue.
